Market Overview

Keryx Biopharmaceuticals Receives FDA Orphan Approval For Treatment of Neuroblastoma

Keryx Biopharmaceuticals (Nasdaq: KERX) receives FDA approval for treatment of Neuroblastoma.

Not FDA Approved for Orphan Indication

Keryx Biopharmaceuticals is up close to 10% this morning.

See Some of the Top Moving Indexes Here.

Posted-In: News FDA Markets Movers

 

Related Articles (KERX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters